Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
There are two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC
Injectable products require sterile manufacturing conditions, tightly controlled formulations, and consistent dosing with every injection
A large real-world cohort of 547,993 matched patients (Vidal/Akiska et al., JAAD International 2026) showed, at 12 months, an increased risk of both telogen effluvium (raised by around 76%) and androgenetic alopecia (raised by around 64%)
Second, GLP-1R activation enhances neurovascular coupling function, improves cerebral blood flow and repairs BBB integrity, blocking the penetration of peripheral inflammatory factors into the center (Wong et al., 2024)
This systemic effect simply cannot occur with topical application
Observed RHR Increases in Clinical Data: + Liraglutide (1.8 mg daily): +610 bpm + Semaglutide (1.02.4 mg weekly): +24 bpm + Tirzepatide (515 mg weekly): +1.53.5 bpm + Exenatide (5-10 g Twice daily): +23 bpm A meta-analysis of over 60 randomized clinical trials found the mean RHR increase with GLP-1RAs to be 2.11 bpm (95% CI: 1.682.54)
US$ 25.77
US$ 28.37
US$ 29.87
US$ 27.32
US$ 27.76
US$ 28.43
US$ 22.04
